USE OF 5-AMINOSALICYLIC ACID FOR TREATMENT OF ULCERATIVE COLITIS IN DIFFERENT DOSAGE MODES

USE OF 5-AMINOSALICYLIC ACID FOR TREATMENT OF ULCERATIVE COLITIS IN DIFFERENT DOSAGE MODES

Preparations of 5-ASA are the first line treatment of ulcerative colitis (UC). Today, in the market of drugs 5-ASA available for the treatment of UC, there are many dosage forms, varying in the coating, method of delivery of active substance and dosing regimens of the drug. The aim of this review is...

Full description

Bibliographic Details
Main Authors:	M. V. Shapina, I. L. Khalif
Format:	Article
Language:	Russian
Published:	Remedium Group LLC 2017-11-01
Series:	Медицинский совет
Subjects:	ulcerative colitis 5-aminosalicylic acid dosage regimen mesalazine
Online Access:	https://www.med-sovet.pro/jour/article/view/2063

Similar Items

Prospects of MMX Mesalazine in Routine Outpatient Treatment of Ulcerative Colitis
by: Yu. P. Uspenskiy, et al.
Published: (2022-03-01)

Perimyocarditis in a Patient with Ulcerative Colitis Treated with 5-Aminosalicylic Acid
by: Hye Young Lee, et al.
Published: (2024-05-01)

5-Aminosalicylic Acid-induced Myocarditis in a Patient with Atypical Ulcerative Colitis
by: Hyo Yeop Song, et al.
Published: (2022-01-01)

5-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis
by: Shinta Mizuno, et al.
Published: (2020-01-01)

Effectiveness of treatment of moderate ulcerative colitis with prolonged mesalazine in real clinical practice
by: O. V. Knyazev, et al.
Published: (2021-10-01)

Synthesis and evaluation of a prodrug of 5-aminosalicylic acid for the treatment of ulcerative colitis
by: Yan Yan, et al.
Published: (2019-12-01)

5-Aminosalicylic Acid Alters the Gut Bacterial Microbiota in Patients With Ulcerative Colitis
by: Jun Xu, et al.
Published: (2018-06-01)

THE RESULTS OF THE USE OF 5-AMINOSALICYLIC ACID AS AN ANTI-RELAPSE AND MAINTENANCE THERAPY ULCERATIVE COLITIS MODERATE SEVERITY IN CLINICAL PRACTICE
by: O. V. Knyazev, et al.
Published: (2018-01-01)

5-Aminosalicylic Acid-Induced Liver Injury in a Patient with Ulcerative Colitis: A Case Report
by: Asuka Watanabe, et al.
Published: (2024-01-01)

Efficacy of mesalazine at ulcerative colitis with nutritional failure
by: A. V. Korolyov, et al.
Published: (2015-03-01)

Mesalazine use tactics in the ulcerative colitis patients
by: A. V. Korolev, et al.
Published: (2013-03-01)

Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease
by: Ajit Sood, et al.
Published: (2020-10-01)

Comparison of efficacy of once daily multimatrix mesalazine 2.4 g/day and 4.8 g/day with other 5-aminosalicylic acid preparation in active ulcerative colitis: a randomized, double-blind study
by: Haruhiko Ogata, et al.
Published: (2018-04-01)

Efficacy and safety of Chinese patent medicine combined with 5-aminosalicylic acid for patients with ulcerative colitis: A network meta-analysis of randomized controlled trials
by: Mingkuan Zhang, et al.
Published: (2024-05-01)

Aminosalicylates in inflammatory bowel disease
by: Vojislav N. Perisic
Published: (2013-10-01)

5-Aminosalicylic Acid Chemoprevention in Inflammatory Bowel Diseases: Is It Necessary in the Age of Biologics and Small Molecules?
by: Hans Herfarth, et al.
Published: (2021-09-01)

Acute Pancreatitis due to pH-Dependent Mesalazine That Occurred in the Course of Ulcerative Colitis
by: Yoshinori Arai, et al.
Published: (2011-10-01)

Management and treatment of distal ulcerative colitis
by: Andrea Calafiore, et al.
Published: (2013-12-01)

DECISION TREE CONSTRUCTION AND COST-EFFECTIVENESS ANALYSIS OF TREATMENT OF ULCERATIVE COLITIS WITH PENTASA®MESALAZINE 2 G SACHET
by: Alvaro Mitsunori NISHIKAWA, et al.

A Case Report and Literature Review of Mesalazine-Induced Kidney Injury in a Pediatric Patient With Ulcerative Colitis
by: Shuo Wang, et al.
Published: (2022-05-01)

Treatment of active ulcerative colitis with Yinmei Kuijie decoction combined with 5-aminosalicylic acid: A non-randomized multicenter prospective observational protocol based on real-world conditions
by: Xinyu Zhang, et al.
Published: (2024-10-01)

Chinese herbal extract granules combined with 5-aminosalicylic acid for patients with moderately active ulcerative colitis: study protocol for a multicenter randomized double-blind placebo-controlled trial
by: Zhaofeng Shen, et al.
Published: (2021-01-01)

Evaluation of the efficacy of MMX mesalazine therapy for moderate ulcerative colitis
by: O. V. Knyazev, et al.
Published: (2021-05-01)

Incidence of Ulcerative Colitis Relapse: A Prospective Cohort Study in Southern Iran
by: Seyed Vahid Hosseini, et al.
Published: (2016-03-01)

Inflammatory Indexes for Assessing the Severity and Disease Progression of Ulcerative Colitis: A Single-Center Retrospective Study
by: Hanyang Lin, et al.
Published: (2022-03-01)

What strategies do ulcerative colitis patients employ to facilitate adherence?
by: Kawakami A, et al.
Published: (2017-01-01)

Synthesis and intestinal metabolism of ursodeoxycholic acid conjugate with an antiinflammatory agent, 5-aminosalicylic acid
by: Ashok K. Batta, et al.
Published: (1998-08-01)

MESALAZINE PLACE IN THERAPY OF ULCERATIVE COLITIS
by: I. G. Bakulin, et al.
Published: (2017-11-01)

A Diagnostic Conundrum in a Newly Diagnosed Ulcerative Colitis Patient Who Presented with Pleuropericardial Effusion
by: Alpaslan Tanoglu, et al.
Published: (2019-06-01)

Current Mesalazine Products: Differences in Enteric-Coated Dosage Forms and Pharmaceutical Risks of Clinical Efficacy Reduction (Review)
by: S. Yu. Serebrova, et al.
Published: (2024-12-01)

Comparative evaluation of the effectiveness of monotherapy of ulcerative colitis with mesalazine MMX and combination therapy with non-prolonged mesalazines with rectal forms
by: O. V. Knyazev, et al.
Published: (2022-08-01)

Integrated Analysis Reveals the Targets and Mechanisms in Immunosuppressive Effect of Mesalazine on Ulcerative Colitis
by: Rong Li, et al.
Published: (2022-05-01)

Acute transverse myelitis in an adult-patient with underlying ulcerative colitis: a case report
by: Yi Yang, et al.
Published: (2022-04-01)

Drugs for the treatment of ulcerative colitis on the pharmaceutical market of Ukraine
by: L. M. Palchak, et al.
Published: (2023-02-01)

SOME ASPECTS OF TREATMENT FOR LEFT-SIDED ULCERATIVE COLITIS
by: P. A. Makarchuk, et al.
Published: (2016-02-01)

Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study
by: Haruhiko Ogata, et al.
Published: (2017-07-01)

A case of ulcerative colitis complicated by a simple appendiceal opening
by: Xiao Liu, et al.
Published: (2024-04-01)

The Synergistic Effects of 5-Aminosalicylic Acid and Vorinostat in the Treatment of Ulcerative Colitis
by: Long He, et al.
Published: (2021-05-01)

Effect of acid-reducing agents on clinical relapse in ulcerative colitis with pH-dependent-released 5-aminosalicylic acid: a multicenter retrospective study in Japan
by: Yosuke Shimodaira, et al.
Published: (2021-04-01)

Clinical Background Factors as Predictors of the Efficacy of 5-Aminosalicylic Acid Suppositories in Patients with Ulcerative Colitis
by: Kazuhiko Uchiyama, et al.
Published: (2023-08-01)